EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy

Kathrin Halfter iD, Michael Staehler iD, Dieter Hölzel iD, Alexander Crispin, Anne Schlesinger-Raab iD

Current Oncology · 16.09.2025 · 32 (9) · 515

DOI: 10.3390/curroncol32090515 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Current Oncology, online erschienen am 16.09.2025. Verfasst von Kathrin Halfter und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Information Processing, Biometry and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Marchioninistraße 15, 81377 Munich, Ge…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Significant changes in renal cell carcinoma (RCC) drug treatment and improved access to abdominal imaging have recently been implemented. The impact of these changes on patient characteristics and prognosis remains to be quantified.

Methods

A population-based cohort of 210,418 RCC cases from the Centre for Cancer Registry Data (ZfKD) diagnosed in Germany between 2000 and 2019 was analyzed in this observational study. Three time periods of diagnosis were defined, the first (2000–2005) functioning as a control. The remaining were defined according to the introduction of tyrosine kinase targeting drugs (2006–2014) and checkpoint inhibitor drugs (2015–2019). Five-year relative survival (RS) trends for each risk group and metastatic RCC (mRCC) were determined using Poisson regression models.

Results

Age at diagnosis and the proportion of low-risk disease increased, while the proportion of mRCC decreased (p < 0.0001). RS improved slightly between the first and last period in low (5-year RS 98.7% vs. 100.9%), intermediate (89.2% vs. 91.9%), and high-risk (76.6% vs. 80.3%), as well as mRCC (28.3% vs. 29.1%). The overall change in prognosis was significant in low (p = 0.0233) and high-risk groups (p = 0.0002), but not in intermediate-risk and mRCC groups. In a multivariate analysis, high-risk ccRCC patients appear to profit from drug treatment advances.

Conclusions

Earlier detection has improved prognosis for the majority of RCC patients. Further efforts should be aimed at diagnosing more mRCC patients earlier, when surgical tumor removal remains feasible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsMolecular Targeted TherapyHumansMaleFemalePrognosisMiddle AgedAgedAdultAged, 80 and over

Stichwörter der Autor:innen

cancer epidemiologyimmunotherapykidney cancerrenal cell carcinomatargeted therapytime trends

Autor:innen und Institutionen

  • Institute of Medical Information Processing, Biometry and Epidemiology (IBE), Faculty of Medicine, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany.
  • Department of Urology, LMU University Hospital, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany.

ORCID-Profile: Kathrin Halfter, Michael Staehler, Dieter Hölzel, Anne Schlesinger-Raab

Zitieren

APA

Halfter, K., Staehler, M., Hölzel, D., Crispin, A., & Schlesinger-Raab, A. (2025). Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy. Current Oncology, 32(9), 515. https://doi.org/10.3390/curroncol32090515

Vancouver

Halfter K, Staehler M, Hölzel D, Crispin A, Schlesinger-Raab A. Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy. Current Oncology. 2025;32(9):515. doi:10.3390/curroncol32090515

BibTeX
@article{Halfter2025,
  author = {Halfter, Kathrin and Staehler, Michael and Hölzel, Dieter and Crispin, Alexander and Schlesinger-Raab, Anne},
  title = {Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {9},
  pages = {515},
  doi = {10.3390/curroncol32090515}
}
Kostenlos starten →